The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Toxicity or Intolerable Dose Criteria
Timeframe: Baseline up to Day 304/End of Treatment (ET)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Categorized by Severity
Timeframe: Baseline up to Day 304/ET
Number of Participants With Treatment Emergent Adverse Events (TEAEs): All Causalities and TEAEs Categorized by Causal Relationship to Study Drug
Timeframe: Baseline up to Day 304/ET
Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) Categorized by Severity
Timeframe: Baseline up to Day 304/ET
Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) Categorized by Causal Relationship to Study Drug
Timeframe: Baseline up to Day 304/ET
Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Categorized by Severity
Timeframe: Baseline up to Day 304/ET
Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Categorized by Causal Relationship to Study Drug
Timeframe: Baseline up to Day 304/ET
Number of Participants With Positive Anti-Drug-Antibodies (ADA) and Neutralizing Antibodies (Nab)
Timeframe: Baseline up to Day 304/ET